The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
An update on PARP inhibitors—moving to the adjuvant setting
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139
Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., & Bonner, W. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5858 · Cited by 5,438
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Ame, J.-C., & de Murcia, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,915
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623
Amé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 856
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Mavaddat, N., Barrowdale, D., Andrulis, I. L., Domchek, S. M., Eccles, D., Nevanlinna, H., Ramus, S. J., Spurdle, A., Robson, M., Sherman, M., et al. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0775 · Cited by 669
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 638
Norquist, B., Wurz, K. A., Pennil, C. C., Garcia, R., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?
Shall, S., & de Murcia, G. (2000) · Mutation Research/DNA Repair · doi:10.1016/s0921-8777(00)00016-1 · Cited by 534
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514
Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., Amnon, A., Bell-McGuinn, K. M., Chen, L.-M., Friedlander, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9215 · Cited by 470
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini, K. S., Viale, G., Loi, S., Bradbury, I., Bliss, J. M., Azim, H. A., Ellis, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2010 · Cited by 465
Self-citationSecondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457
Cameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., Steger, G. G., Suter, T. M., Toi, M., Parmar, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70335-8 · Cited by 432
Oddoux, C., Struewing, J. P., Clayton, C. M., Neuhausen, S., Brody, L. C., Kaback, M., Haas, B., Norton, L., Borgen, P., Jhanwar, S., et al. (1996) · Nature Genetics · doi:10.1038/ng1096-188 · Cited by 381
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 352
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, L. J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 336
PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
Rulten, S. L., Fisher, A. E. O., Robert, I., Zuma, M. C., Rouleau, M., Ju, L., Poirier, G., Reina-San-Martin, B., & Caldecott, K. W. (2011) · Molecular Cell · doi:10.1016/j.molcel.2010.12.006 · Cited by 326
Kummar, S., Kinders, R., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J., Monks, A., Low, J. A., Chen, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7681 · Cited by 326
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations
Rennert, G., Bisland-Naggan, S., Barnett-Griness, O., Bar-Joseph, N., Zhang, S., Rennert, H. S., & Narod, S. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070608 · Cited by 302
Bang, Y.-J., Im, S.-A., Lee, K.-W., Cho, J. Y., Song, E.-K., Lee, K. H., Kim, Y. H., Park, J. O., Chun, H. G., Zang, D. Y., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0320 · Cited by 290
Targeted therapy for cancer using PARP inhibitors
Lord, C. J., & Ashworth, A. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.016 · Cited by 289
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
Riffell, J. L., Lord, C. J., & Ashworth, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3868 · Cited by 285
Boehler, C., Gauthier, L. R., Mortusewicz, O., Biard, D. S., Saliou, J.-M., Bresson, A., Sanglier-Cianferani, S., Smith, S., Schreiber, V., Boussin, F., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016574108 · Cited by 277
The role of poly(ADP-ribose) in the DNA damage signaling network
Malanga, M., & Althaus, F. R. (2005) · Biochemistry and Cell Biology · doi:10.1139/o05-038 · Cited by 275
Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259
Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability
Fagagna, F. D. D., Hande, M. P., Tong, W.-M., Lansdorp, P. M., Wang, Z.-Q., & Jackson, S. P. (1999) · Nature Genetics · doi:10.1038/12680 · Cited by 255
O'Shaughnessy, J., Schwartzberg, L. S., Danso, M. A., Rugo, H. S., Miller, K., Yardley, D. A., Carlson, R. W., Finn, R. S., Charpentier, E., Freese, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.1007 · Cited by 245
Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G., & Kaufmann, S. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2890 · Cited by 212
DNA Repair: The Importance of Phosphorylating Histone H2AX
Lowndes, N. F., & Toh, G. W.-L. (2005) · Current Biology · doi:10.1016/j.cub.2005.01.029 · Cited by 206
Kummar, S., Ji, J., Morgan, R., Lenz, H.-J., Puhalla, S. L., Belani, C. P., Gandara, D. R., Allen, D., Kiesel, B., Beumer, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2821 · Cited by 199
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., Singer, C. F., Lowe, E. S., Watkins, C. L., & Carmichael, J. (2013) · Breast Cancer Research · doi:10.1186/bcr3484 · Cited by 184
Lee, J.-M., Hays, J. L., Annunziata, C. M., Noonan, A. M., Minasian, L., Zujewski, J. A., Yu, M., Gordon, N., Ji, J., Sissung, T. M., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju089 · Cited by 184
Plummer, R., Lorigan, P., Steven, N., Scott, L., Middleton, M. R., Wilson, R. H., Mulligan, E., Curtin, N., Wang, D., Dewji, R., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2113-1 · Cited by 179
Hastak, K., Alli, E., & Ford, J. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4521 · Cited by 176
Liu, J. F., Tolaney, S. M., Birrer, M., Fleming, G. F., Buss, M. K., Dahlberg, S. E., Lee, H., Whalen, C., Tyburski, K., Winer, E., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.020 · Cited by 174
Alli, E., Sharma, V. B., Sunderesakumar, P., & Ford, J. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4016 · Cited by 171
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Rajan, A., Carter, C. A., Kelly, R. J., Gutierrez, M., Kummar, S., Szabo, E., Yancey, M. A., Ji, J., Mannargudi, B., Woo, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2425 · Cited by 164
Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer
Anders, C. K., Winer, E. P., Ford, J. M., Dent, R. A., Silver, D. P., Sledge, G. W., & Carey, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0939 · Cited by 159
Samol, J., Ranson, M., Scott, E., Macpherson, E., Carmichael, J., Thomas, A., & Cassidy, J. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9682-9 · Cited by 158
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Bouwman, P., & Jonkers, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0225 · Cited by 158
Isakoff, S. J., Overmoyer, B. A., Tung, N., Gelman, R. S., Giranda, V. L., Bernhard, K. M., Habin, K. R., Ellisen, L. W., Winer, E. P., & Goss, P. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.1019 · Cited by 152
Dean, E. J., Middleton, M. R., Pwint, T. P., Swaisland, H., Carmichael, J., Goodege, P., & Ranson, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.555 · Cited by 125
Khan, O., Gore, M. E., Lorigan, P. C., Stone, J., Greystoke, A., Burke, W., Carmichael, J., Watson, A. J., McGown, G., Thorncroft, M. R., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.8 · Cited by 123
Guarini, A. R., Marinelli, M., Tavolaro, S., Bellacchio, E., Magliozzi, M., Chiaretti, S., Propris, M. S. D., Peragine, N., Santangelo, S., Paoloni, F. P., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.049270 · Cited by 121
Miknyoczki, S. J., Chang, H., Grobelny, J. V., Pritchard, S., Worrell, C. S., McGann, N., Ator, M. A., Husten, J., Deibold, J., Hudkins, R. L., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0062 · Cited by 100
Bundred, N., Gardovskis, J., Jaskiewicz, J., Eglitis, J., Paramonov, V., McCormack, P., Swaisland, H., Cavallin, M., Parry, T., Carmichael, J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9922-7 · Cited by 89
PARP inhibitors: polypharmacology versus selective inhibition
Ekblad, T., Camaioni, E., Schuler, H., & Macchiarulo, A. (2013) · FEBS Journal · doi:10.1111/febs.12298 · Cited by 82
Mechanisms of Resistance to PARP Inhibitors—Three and Counting
Fojo, T., & Bates, S. E. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0514 · Cited by 79
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
Bono, J. S. D., Mina, L. A., Gonzalez, M., Curtin, N. J., Wang, E., Henshaw, J. W., Chadha, M. K., Sachdev, J. C., Matei, D. E., Jameson, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2580 · Cited by 76
Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T., Yamada, K., Asahina, H., Kawata, T., Shi, X., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02179.x · Cited by 73
Tucker, C. L., & Fields, S. (2003) · Nature Genetics · doi:10.1038/ng1103-204 · Cited by 72
Oza, A. M., Cibula, D., Oaknin, A., Poole, C. J., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.5001 · Cited by 66
Schelman, W. R., Sandhu, S. K., Garcia, V. M., Wilding, G., Sun, L., Toniatti, C., Stroh, M., Kreischer, N., Carpenter, C. L., Molife, L. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3102 · Cited by 57
Drew, Y., Ledermann, J. A., Jones, A. L., Hall, G. D., Jayson, G. C., Highley, M., Rea, D., Glasspool, R. M., Halford, S. E. R., Crosswell, G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3104 · Cited by 37
Penson, R. T., Whalen, C., Lasonde, B., Krasner, C. N., Konstantinopoulos, P. A., Stallings, T. E., Bradley, C. R., Birrer, M. J., & Matulonis, U. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.5004 · Cited by 33
Shi, L., Ko, S., Kim, S., Echchgadda, I., Oh, T.-S., Song, C. S., & Chatterjee, B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805980200 · Cited by 32
Kristeleit, R. S., Shapiro, G. I., LoRusso, P. M., Infante, J. R., Flynn, M., Patel, M. R., Tolaney, S. M., Hilton, J. F., Calvert, H., Giordano, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2585 · Cited by 24
Konstantinopoulos, P. A., & Cannistra, S. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1489 · Cited by 12
Cited by
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
Denkert, C., Liedtke, C., Tutt, A., & von Minckwitz, G. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32454-0 · Cited by 872
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Metadata
- Authors
- Sonnenblick, A., de Azambuja, E., Azim, H. A., & Piccart, M.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2014-10-07
- Volume
- 12
- Issue
- 1
- Pages
- 27-41
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2163294504
- Cited by
- 373
- References
- 82
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.